Global Cell Therapy Market Size, Trends, Growth, Forecast: By Type: Stem Cell, Non-Stem Cell (Dendritic Cell, CART-Cell); By Type of Therapy: Autologous, Allogeneic; By Therapeutic Area: Musculoskeletal Disorders, Cardiovascular Diseases, Neurological Disorders, Others; By End User; Regional Anlysis; Supplier Landscape; 2024-2032

Global Cell Therapy Market Size

The global cell therapy market was valued at USD 16.30 billion in 2023, driven by the rising burden of chronic diseases and increased funding for cell therapy clinical studies across the globe. The market is expected to grow at a CAGR of 18.1% during the forecast period of 2024-2032, with the values likely to reach USD 72.84 billion by 2032.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Global Cell Therapy Market Outlook

• The rising burden of chronic diseases such as cancer and cardiovascular conditions coupled with the growing aging population more susceptible to developing a chronic health issue is expected to directly impact the market demand for effective cell therapies.

• The U.S. cell therapy market holds a significant market share owing to substantial financial support from both government and private bodies in the development of novel cell therapy products and the presence of a favorable regulatory environment to expedite the market entry of such advanced cell therapy products.

• Increased strategic partnerships and equity investments in the cell therapy domain are major market trends.

Global Cell Therapy Market Overview

Cell therapy is increasingly being used to treat patients with cancer, weakened immune systems, infectious diseases, and neurological disorders, which, in turn, surges its demand. Further, the COVID-19 pandemic has positively impacted pharmaceutical and biotechnology-based research projects, including cell therapy. As the SARS-CoV-2 virus critically damages the lungs and immune system of the infected patient, various cell therapies are being explored as a potential treatment for the novel disease. The development of global cell therapy market is being driven by the increasing research activities and funding in the medical industry. Moreover, cell therapy can substantially improve survival rates of end-stage patients with acute respiratory distress syndrome (ARSD) associated with SARS-CoV-2, which is providing further impetus to the industry growth.

The market is poised for significant growth due to the rising innovations in gene editing technologies such as CRISPR-Cas9 and the advancements in stem cell research that are expanding the applications of cell therapies in regenerative medicine. The growing burden of cancer fuels the demand for novel treatments such as CAR-T cell therapy, which impacts the cell therapy market growth. Improvements in regulatory frameworks are enabling a faster introduction of promising therapies in the market, which boosts the market share. Other factors that influence the market growth include the surge in investment from venture capitalists and private equity firms in biotech companies focused on cell therapy, increased partnerships between pharmaceutical companies and biotech firms, and advances in manufacturing processes of cell therapies.

Global Cell Therapy Market Trends

Increased Merger and Acquisition Activities to Meet Rising Market Demand

The market is witnessing increased merger and acquisition initiatives to pool resources and expertise in order to expedite the development of novel cell therapies. For instance, in April 2024, the biotechnology company Century Therapeutics acquired United States-based cell therapy company Clade Therapeutics, Inc., in a deal that requires Century to pay USD 35 million upfront and an additional USD 10 million as milestone payments. The biotech firm plans to leverage this acquisition to expand its pipeline of autoimmune and cancer therapies. It gains ownership of Clade’s three preclinical allogeneic induced pluripotent stem cell (iPSC)-derived cell candidates including CLDE-308 (a CD19 targeting αβ iT cell programme for treating B-cell malignancies and autoimmune diseases), CLDE-361 (a B-cell maturation antigen (BCMA) αβ iT cell programme for the treatment of myasthenia gravis), and an undisclosed candidate for solid tumors treatment along with its αβ iT platform. Such strategic partnerships that acquire promising clinical candidates in different disease indications are expected to elevate the cell therapy market value.

Surge in Demand for CAR T-Cell Therapy Drives Market Growth

Chimeric Antigen Receptor (CAR) T-cell therapy is a type of cellular immunotherapy that has emerged as a breakthrough in cancer treatment. This cell-based gene therapy has shown positive results in treating certain types of blood cancers, such as leukemia and lymphoma. The high efficacy of CAR T-cell therapy especially in patients who were not responding to other standard treatments has augmented the interest and demand for this new treatment, which influences the dynamics of the cell therapy market.

In April 2024, the Indian president launched the first indigenously developed CAR T-cell therapy to treat cancer, created by the Indian Institute of Technology (IIT) Bombay and Tata Memorial Centre, as part of the Make in India initiative. It was reported that this indigenously developed cancer treatment NexCAR19 CAR T-cell therapy is one-tenth of its price outside the country, with the therapy cost amounting to roughly INR 4 crore abroad to INR 30 lakh in India. The lower cost of the treatment is a significant milestone in the healthcare sector, making CAR-T cell therapy affordable and more accessible to the growing patient pool. Thus, increased government support to advance cell therapy innovations is projected to bolster market growth in the coming years.

Rising Equity Investments to Support the Development of Novel Cell Therapy Products Elevates Market Value

One of the major market trends is the increased equity investments to propel the development of novel cell therapy products. Substantial investments drive intensive research and development (R&D) activities, preclinical studies, and the advancement of potential therapies into clinical trials. Adequate funding also ensures that innovative cell therapies secure regulatory approval and gain market access, which contributes to the growing share of the cell therapy market.

Following the equity investment and research partnership agreement in November 2023, multinational pharmaceutical and biotechnology company AstraZeneca concluded an equity investment in Cellectis, a clinical-stage biopharmaceutical company focused on developing the Next-Generation CAR T-Cells to cure cancer, in May 2024. Under the agreement, the biotech firms plan to develop up to ten novel cell and gene therapy products in areas of high unmet medical needs such as oncology, immunology, and rare diseases, by employing Cellectis’ gene editing technologies and manufacturing expertise. As part of this research partnership deal, Cellectis received USD 105 million as an initial payment from AstraZeneca in Q4 2023. The rising equity investments in the cell therapy sector is likely to boost the market share in the forecast period.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Recent Developments in the Market

Increased Investments in Cell Therapy Manufacturing Facilities

In February 2024, AstraZeneca announced an investment of USD 300 million in a Rockville (Maryland) facility for the discovery and development of cell therapies. The pharmaceutical giant’s new site will generate 150 jobs, with the company planning to first focus on manufacturing the cell therapies so that clinical trials can be conducted. AstraZeneca is reported to be advancing early-stage clinical trials of several cell therapy candidates in various types of cancer including prostate and liver cancer. This investment initiative was preceded by AstraZeneca’s acquisition of Neogene Therapeutics (developer of next-generation T-cell receptor therapies) and other agreements with cell therapy developers. Such major investments in enhancing the manufacturing capabilities of cell therapy production units are poised to fuel the growth of the market.

Surge in Clinical Trial Activities of Novel Cell Therapy Products

The surge in clinical trials of cell therapy candidates is set to drive the cell therapy market growth. In May 2024, Orca Bio, a clinical-stage biotechnology company specializing in developing allogeneic cell therapy products, announced the presentation of positive clinical outcomes of its lead investigational allogeneic T-cell immunotherapy, Orca-T, in patients with acute myeloid leukemia (AML) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 to June 4. The findings revealed overall survival and relapse-free survival were 100% and 82.5%, respectively, at 12 months in 37 acute myeloid leukemia patients. Besides, the non-relapse mortality at 12 months was reported to be 0%. Orca-T is currently undergoing Phase 3 clinical trials for further assessment of its efficacy and safety profile. Increased focus on the clinical development of high-precision cell therapy candidates is likely to augment the market demand.

Global Cell Therapy Market Segmentation

Market Breakup by Cell Type

• Stem Cell
  • Bone Marrow Derived Mesenchymal Stem Cell
  • Hematopoietic Stem Cells
  • Umbilical Cord Derived Stem Cell
  • Adipose Derived Stem Cell
  • Skin Stem Cells
  • Induced Pluripotent Stem Cells
  • Others

• Non-Stem Cell (Dendritic Cell, CART-Cell)

Market Breakup by Type of Therapy

• Autologous

• Allogeneic

Market Breakup by Therapeutic Area

• Musculoskeletal Disorders

• Cardiovascular Diseases

• Neurological Disorders

• Oncological Disorders

• Dermatology

• Inflammatory and Autoimmune disorders

• Others

Market Breakup by End User

• Hospitals and Clinics

• Regenerative Medicine Centers

• Diagnostic and Research Centers

• Others

Market Breakup by Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East and Africa

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Global Cell Therapy Market Share

Market Segmentation by Cell Type is Expected to Drive Substantial Market Growth

Based on the cell type, the market is segmented into stem cells and non-stem cells. The stem cell segment comprises bone marrow derived mesenchymal stem cells, hematopoietic stem cells, umbilical cord derived stem cells, adipose derived stem cells, skin stem cells, and induced pluripotent stem cells, among others, whereas non-stem cells segment includes dendritic cells and car t-cells.

The increasing application of stem cells in regenerative medicine and treatment of various diseases is poised to support the cell therapy market growth. Bone marrow derived mesenchymal stem cells (BM-MSC) are taken from bone marrow. They have the ability to differentiate into various cell types and are useful in treating bone and cartilage diseases, and cardiovascular conditions. On the other hand, hematopoietic stem cells (HSC) are taken from bone marrow, peripheral blood, or umbilical cord blood. These cells are responsible for blood cell formation and are increasingly used in the treatment of blood disorders such as leukemia, lymphoma, and anemia.

The cell therapy market is also experiencing increased interest in non-stem cell therapies including dendritic cells and CAR T-cells. Such cell therapies are utilized in cancer immunotherapy to destroy cancer cells by leveraging the body's immune system. This segment is anticipated to drive significant market demand with the rising cases of cancer and the need for effective treatment approaches.

North America and Europe are Leading the Market Share

Historically, North America dominated the cell therapy market due to the presence of adequate financial support from both government and private bodies in the development of novel cell therapy products and the increased awareness and acceptance of cell therapies among healthcare providers and patients. In the United States, the rising burden of chronic diseases (such as heart disease, cancer, diabetes, obesity, and hypertension) drives the demand for advanced therapies. The US Department of Health and Human Services estimated that around 129 million people in the United States have at least 1 major chronic disease. Since cell therapies can offer promising treatment options for these chronic conditions, the market share is expected to grow in the coming years. Thus, the cell therapy market in North America, particularly in the United States, is anticipated to witness steady growth owing to increased demand for effective cell therapies, growing interest in regenerative medicine and personalized treatment approaches, and rising regulatory support for innovative treatments.

Europe also holds a significant share of the overall cell therapy industry, with France and the United Kingdom being some of the dominant regional markets. The increasing research and development activities in France, owing to the presence of some of the leading biotech and research institutions of cell therapy, are bolstering the market growth. In addition, the French biotech institutions, with government support, are contributing to the development of innovative cell therapies. Moreover, the introduction of various favorable government initiatives to aid research activities is invigorating the industry growth, hence contributing to the overall growth of the cell therapy market in the European region. For instance, the United Kingdom government initiated the Human-Induced Pluripotent Stem Cells Initiative (HipSCi) to bring preclinical, clinical, and pharmacological work on stem cells under one institution and increase the accessibility of induced pluripotent stem cell (iPSC) resources to identify new mechanisms.

Competitive Landscape

The key features of the global cell therapy market report include patent analysis, clinical trial analysis, grant analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:

Vericel Corporation

Vericel Corporation is a public, American biopharmaceutical company, with a manufacturing facility in Massachusetts (Cambridge). It develops and markets advanced cell therapies in areas of sports medicine and severe burn care and has a robust presence in the U.S. cell therapy market. The company has a strong product portfolio including autologous cultured chondrocytes on porcine collagen membrane (MACI) to treat cartilage defects and Epicel cultured epidermal autografts for skin replacement. The biopharma company also holds an exclusive license for NexoBrid (anacaulase-bcdb) in North America for treating severe thermal burns.

Kolon TissueGene Inc.

This biotechnology company specializes in the development of cell and gene therapies for the treatment of osteoarthritis and other orthopedic conditions. Its novel cell and gene therapy for knee osteoarthritis, INVOSSA-K, was approved in South Korea in 2017 but was later retracted in 2019. Kolon TissueGene is actively working on the preclinical and clinical development of its pipeline products to expand its cell and gene therapies portfolio for treating various orthopedic and musculoskeletal disorders and is expected to significantly contribute to bringing cell therapy innovations into the market.

JCR Pharmaceuticals Co. Ltd

This Japanese biopharmaceutical company focuses on the development and commercialization of innovative therapies, including cell and gene therapies. Its allogeneic cell therapy JR-031 (Temcell HS Inj.) is a mesenchymal stem cell (MSC) therapy used to treat graft-versus-host disease (GVHD). The company heavily invests in R&D activities and has several cell therapy candidates in various stages of preclinical and clinical development. The pharmaceutical company is also aiming for global commercialization via strategic partnerships with international companies and is likely to elevate the cell therapy market value in the forecast period.

MEDIPOST Co. Ltd.

MEDIPOST Co. Ltd., a South Korean biotechnology company, has a prominent presence in the market. Its allogeneic umbilical cord blood-derived mesenchymal stem cell therapy, Cartistem, is designed for the treatment of knee cartilage defects and osteoarthritis. The company is known to actively collaborate with academic institutions, research organizations, and other biotech companies to advance and expand its cell therapy pipeline.

Other players in the cell therapy market include Osiris (Mesoblast), Stemedica Cell Technologies Inc., ImmunoACT, Castle Creek Biosciences, Inc., PHARMICELL Co. Ltd, ANTEROGEN.CO.LTD, Novartis AG, Celgene Corp. (Bristol-Myers Squibb Company), Allogene Therapeutics Inc., and Stempeutics Research Pvt. Ltd, among others.

Key Highlights of the Report

Key Questions Answered in the Global Cell Therapy Market Report

• What is the cell therapy market?
• What is the cell therapy market forecast for 2024-2032?
• What are the key types of cell therapies? 
• What factors are driving the growth of the cell therapy market?
• What is market segmentation based on cell type?
• What is the market breakup based on the type of therapy?
• What is the market breakup based on the therapeutic area?
• Who are the major end users in the market?
• What are the potential applications of cell therapy?
• What challenges does the cell therapy market face?
• What are the regional markets covered in the EMR report?
• Which regional market is expected to lead the market share in the forecast period? 
• Which country is expected to experience expedited growth during the forecast period? 
• Who are the major players in the global cell therapy market?
• Which cell type will dominate the market share? 
• Which type of therapy is expected to have a high market value in the coming years?
• Which therapeutic area will experience the highest demand in the market segment?
• Which end user is likely to contribute significantly to the market growth? 
• What are some recent developments in the cell therapy market? 
• How is the regulatory landscape evolving for cell therapies?
• How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?

Cell Therapy Market Report Snapshots

Cell Therapy Market Size

Cell Therapy Market Trends

Cell Therapy Market Share

Cell Therapy Companies

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.